Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
AOD9604 supplementation had no adverse effects compared to full-length hGH treatment
Medical Disclaimer: This article discusses B12 injections and compounded lipotropic shots for informational purposes only
Important for mood regulation and neurological health
Pain Relief: LDN is known to reduce pain by blocking the reception of pain signals and increasing endorphins, which naturally alleviate pain
US$ 29.54
US$ 22.93
US$ 27.60
US$ 26.59
US$ 24.48
